BPIFA3

Across TCGA pan-cancer cohorts, BPIFA3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BPIFA3 data layer compared with 18 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BPIFA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BPIFA3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where BPIFA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	0.917	0.612	.011	16	view →
CCRCC	DFS	Median	All	0.832	0.632	.006	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
LSCC	OS	Tertile	III,IV	0.868	0.483	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BPIFA3–HNSC (OS)

Open the HNSC breakdown →